Belviq(Lorcaserin) is a relatively new weight loss medication that was approved by the United States Food and Drug Administration (USFDA) in June of 2012 as an a long term treatment for obesity or overweight status. The other new weight loss medication, Qsymia, was also approved by the USFDA around the same time in June of 2012.
- 1 Background
- 2 Weight loss medications
- 3 New weight loss medications Qsymia and Belviq
- 4 Who is a candidate for Belviq?
- 5 How Does Belviq Work?
- 6 How is Belviq taken?
- 7 Clinical trials of Belviq
- 8 Amount of weight loss with Belviq
- 9 Locations for Belviq
- 10 Need help losing weight?
- 11 Follow weight loss and wellness on social media
As the United States and the rest of the world fights an epidemic of obesity or being overweight, there has long been a need for medications that curb the appetite, stimulate metabolism and assist in patients efforts at losing weight under the supervision of a weight loss physician. See the main article diet pills.
Weight loss medications
In 2012, the FDA approved two new weight loss medications Qsymia and Belviq after years of rejecting many other weight loss medications. There are other traditional and time tested weight loss medications such as Phentermine, Phendimetrazine etc.
What works and what does not for losing weight?
New weight loss medications Qsymia and Belviq
Medications for weight loss (diet pills) reviewed!
Who is a candidate for Belviq?
You may be talk to your doctor about Belviq or Qsymia if you:
- 18 years or older
- Have a Body mass index of 30 or more
- Have a Body mass index of 27 or more and have one or more medical problems related to overweight status.
How Does Belviq Work?
Belviq(lorcaserin) works by activating a part of the mind that controls hunger called appetite center.
How is Belviq taken?
Belviq is a 10 mg tablet taken twice a day.
Clinical trials of Belviq
- Belviq was investigated or studied in three clinical trials that continued from 52 to 104 weeks with nearly 8,000 obese and overweight patients.
Amount of weight loss with Belviq
The mean weight decrease for patients taking Belviq ranged from 3 to 3.7 percent over those taking a placebo.
- in patients without type 2 diabetes, about 47 per-cent of patients lost at least 5 percent of their weight compared with 23 per hundred of patients treated with placebo.
Belviq should be ceased or stopped if a patient falls short or fails to lose 5 per hundred of their weight after 12 weeks of treatment,as it is improbable that continued treatment will be successful.
Locations for Belviq
- W8MD medical weight loss centers locations do offer Belviq, Qsymia and other weight loss medications when medically appropriate.
Need help losing weight?
W8MD's 52 weeks of weight loss videos - w8md weight loss diet
Weight loss services